Navigation Links
AtriCure Announces Web Cast and Conference Call of Fourth Quarter and Full Year 2007 Financial Results
Date:2/5/2008

About AtriCure, Inc.

AtriCure, Inc. is a medical device company and a leader in developing, manufacturing and selling innovative cardiac surgical ablation systems designed to create precise lesions, or scars, in cardiac, or heart, tissue. Medical journals have described the adoption by leading cardiothoracic surgeons of the AtriCure Isolator(R) bipolar ablation system as a treatment alternative during open-heart surgical procedures to create lesions in cardiac tissue to block the abnormal electrical impulses that cause atrial fibrillation, or AF, a rapid, irregular quivering of the upper chambers of the heart. Additionally, medical journals and leading cardiothoracic surgeons have described the AtriCure Isolator(R) system as a promising treatment alternative for patients who may be candidates for sole-therapy minimally invasive procedures. AF affects more than 2.5 million Americans and predisposes them to a five-fold increased risk of stroke.

The FDA has cleared the AtriCure Isolator(R) bipolar ablation system, including the new Isolator Synergy(TM) ablation clamps and the AtriCure multifunctional bipolar Pen, for the ablation, or destruction, of cardiac tissues during surgical procedures. Additionally, the FDA has cleared the AtriCure Pen for temporary pacing, sensing, stimulating and recording during the evaluation of cardiac arrhythmias. To date, the FDA has not cleared or approved AtriCure's products for the treatment of AF. AtriCure's left atrial appendage clip system has not been approved for commercial use. It is currently being used in clinical evaluations in Europe.

Contact:

AtriCure, Inc.

Julie A. Piton

Vice President and Chief Financial Officer

(513) 755-4561

jpiton@atricure.com


'/>"/>
SOURCE AtriCure, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. AtriCure to Present at BMO Capital Markets 2007 Healthcare Conference
2. AtriCure Reports Third Quarter 2007 Financial Results
3. AtriCure Ranked 80th in Deloittes Technology Fast 500
4. AtriCure Announces Web Cast and Conference Call of Third Quarter 2007 Financial Results
5. Published Results Using AtriCure Minimally Invasive Products
6. AtriCure to Present at ThinkEquity Partners 5th Annual Growth Conference
7. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
8. AtriCure to Present at Roth Capital Partners 2007 New York Conference
9. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
10. California Department of Social Services Announces Improved Access to Disability Payments to Homeless Individuals
11. LOreal USA Announces Three-Year Support of Womens Dermatologic Society Foundation Community Outreach
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Preventing lung scarring may extend lives of lung cancer patients 2Health News:Rhode Island Hospital lands $11.1M grant from National Institutes of Health 2Health News:Rhode Island Hospital lands $11.1M grant from National Institutes of Health 3Health News:Rhode Island Hospital lands $11.1M grant from National Institutes of Health 4Health News:Rhode Island Hospital lands $11.1M grant from National Institutes of Health 5Health News:Kellogg School of Management Announces 'Code Red' 2Health News:Charlie Rose Science Series to Focus on the Challenge of Researching and Implementing Effective Treatments for Diseases of the Developing World 2Health News:Charlie Rose Science Series to Focus on the Challenge of Researching and Implementing Effective Treatments for Diseases of the Developing World 3Health News:Charlie Rose Science Series to Focus on the Challenge of Researching and Implementing Effective Treatments for Diseases of the Developing World 4Health News:The Organic Trade Association Hails Preliminary Research Findings Showing Nutritional Benefits of Organic Products 2Health News:HealthShares(TM) Announces Change to the HealthShares(TM) Ophthalmology Index and the HealthShares(TM) Composite Index 2Health News:HealthShares(TM) Announces Change to the HealthShares(TM) Ophthalmology Index and the HealthShares(TM) Composite Index 3
Breaking Medicine Technology:Boston Scientific Announces Pricing of $2 Billion of Senior Notes 2Boston Scientific Announces Pricing of $2 Billion of Senior Notes 3Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 2Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 3Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 4Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 656 Year Old Grandmother Announces Attempt to Become First Woman to Complete the 4 Deserts 28TM 29 in Under a Year 56088 156 Year Old Grandmother Announces Attempt to Become First Woman to Complete the 4 Deserts 28TM 29 in Under a Year 56088 256 Year Old Grandmother Announces Attempt to Become First Woman to Complete the 4 Deserts 28TM 29 in Under a Year 56088 3Pelosi and Reid Invite President Obama to Address Congress 56085 1Chindex International Announces September Investor Conferences Participation 56083 1Chindex International Announces September Investor Conferences Participation 56083 2